- Hemostemix Inc. (HEM) signs a contract to complete a transfer ACP-01 to Dr. James Shapiro’s laboratory at the University of Alberta
- ACP-01 is a tissue cell precursor that demonstrates improved formation of new blood cells in the heart and limbs of individuals who have difficulty getting blood to vital organs
- The combination of ACP-01 and cell transplants from human stem cells show promise in the treatment of diabetes
- The receiving team will create a new product by combining the two formulations by beginning with stem cells
- Hemostemix Inc. (HEM) is up 6.90 per cent trading at $0.16 per share as of 1:58 p.m. EST
Hemostemix Inc. (HEM) has signed a contract to transfer ACP-01 to Dr. James Shapiro’s laboratory at the University of Alberta.
ACP-01 is a tissue cell precursor that demonstrates improved formation of new blood cells in the heart and limbs of people who have difficulty getting blood to vital organs.
The combination of ACP-01 and cell transplants from human stem cells show promise in the treatment of type one diabetes.
Dr. Shapiro added,
“I am particularly excited about the potential of ACP-01 to improve early engraftment, survival and function of transplanted human islets and stem cell products, and we are poised to explore this potential,”
The receiving team will create a new product by combining the two formulations by beginning with stem cells.
After which the team will complete preclinical studies in vivo, then move to first-in-human testing.
Dr. Shapiro led the clinical team with the “Edmonton Protocol” stem cell transplant success.
He was the principal investigator of an international trial that replicated the Edmonton protocol study success, which was published in the NEJM in 2006.
Dr. Shapiro has brought in more than $85 million in grants and support for work on stem cell transplantation.
His team is actively researching personalized medicine approaches to pancreatic and other cancers, using a pre-tissue under-the-skin implantation model.
“We believe that improving cell survival is key to improving short-term and long-term cell transplant function in our diabetes trials, as we look ahead to future cell therapy treatments that could one day reverse diabetes,” said Dr. Shapiro.
Hemostemix Inc. (HEM) is up 6.90 per cent trading at $0.16 per share as of 1:58 p.m. EST.
